Sally Yanchus: Okay. And is there a lot of interest among the clinicians that your salesforce targets? I mean, are they aware of this type of test of, I guess, how much interest and awareness is there among the physicians?
Nicole Sandford: Yes, there’s a lot of awareness and a lot of excitement for an endometriosis test. And our simple advisory board that we put together in 2023 has been really helpful in helping us to understand the need for, and then we dose this quite candidly, what we hear over and over again is there’s nothing currently, and so anything is really helpful, right? The only way to diagnose endometriosis today is through laparoscopic surgery, which is not ideal for anybody, but it’s certainly even less ideal when you’re talking about a pediatric patient, women with other comorbidities like obesity. These are people who are not good candidates for any surgery. So there’s a lot of excitement and interest in the fact that we have now launched the first-ever protein-based blood test or completed the design [indiscernible], but completed the design of them and verified the performance of a noninvasive test for endometriosis and endometrioma being the first target for EndoCheck.
So a lot of excitement there. Our poster at the SRI Conference related to EndoCheck was the most — one of the most popular poster presentations there. So I think it tells us a lot about the excitement that’s happening.
Sally Yanchus: That’s great to hear. And are there currently therapies on the market to treat endometriosis? And what’s the [indiscernible] there?
Nicole Sandford: Yes. There’s 2 — well, there’s several that have been around for a long time, and then there’s 2 that are more recent additions to the field. Both are indicated for pain management for endometriosis. AbbVie has a drug on the market. And Myovant, which is now part of Sumitovant, also has a drug on the market. But when you look forward into the future, there are many therapies in development and the need for a noninvasive or nonsurgical diagnostic is one of the things that hold enough progress. So we see that the creation of an effective diagnostic will help accelerate the development of the drug therapies as well.
Operator: [Operator Instructions] At this time, there are no further questions in the queue. I will now turn it back to Nicole Sandford for closing remarks.
Nicole Sandford: Great. Thank you, operator, and thank you, everyone, for joining us. We really appreciate the support of our shareholders. We really appreciate all of you joining us today. Hopefully, you’re hearing the excitement in my voice and Torsten’s voice. The company is really well-positioned in 2024, and we’re excited to get back to you in just a few short weeks for our first quarter call. So thanks again, and enjoy a quiet day tomorrow.
Operator: Thank you. The conference of Aspira Women’s Health has now concluded. Thank you for your participation. You may now disconnect your lines.
